The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy

Eomes Impedes Durable Response to Tumor Immunotherapy by Inhibiting Stemness, Tissue Residency, and Promoting the Dysfunctional State of Intratumoral CD8+ T Cells

(2021) Runzi Sun et al.   Frontiers in Cell and Developmental Biology

Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment

(2020) Min Yang et al.   OncoImmunology

Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer

(2020) Lei Zhang et al.   CELL

Tumor-Derived IL33 Promotes Tissue-Resident CD8+ T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy

(2020) Lujun Chen et al.   Cancer Immunology Research

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

(2019) Moshe Sade-Feldman et al.   CELL

The role of NK cells and CD39 in the immunological control of tumor metastases

(2019) Haiyan Zhang et al.   OncoImmunology

Allies or Enemies—The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment

(2019) Lisa Haas et al.   Frontiers in Immunology

CD4+ T Cell Help Is Required for the Formation of a Cytolytic CD8+ T Cell Subset that Protects against Chronic Infection and Cancer

(2019) Ryan Zander et al.   IMMUNITY

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

(2018) Xiaolei Li et al.   Journal of Hematology & Oncology

Adoptive Transfer of Interleukin-21-stimulated Human CD8+ T Memory Stem Cells Efficiently Inhibits Tumor Growth

(2018) Yingshi Chen et al.   JOURNAL OF IMMUNOTHERAPY

Tissue-Resident Memory CD8+ T Cells: From Phenotype to Function

(2018) David J. Topham et al.   Frontiers in Immunology

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

(2018) Young Kwang Chae et al.   Journal for ImmunoTherapy of Cancer

Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models

(2017) Katherine E. Lewis et al.   OncoImmunology

A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy

(2016) C. Alvarez-Fernández et al.   Journal of Translational Medicine

Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype

(2015) Meng Xu et al.   JOURNAL OF IMMUNOLOGY

Release from Regulatory T Cell-Mediated Suppression during the Onset of Tissue-Specific Autoimmunity Is Associated with Elevated IL-21

(2014) L. E. Clough et al.   JOURNAL OF IMMUNOLOGY

Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity

(2014) J. Bastid et al.   Cancer Immunology Research

Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study

(2014) Shailender Bhatia et al.   Journal for ImmunoTherapy of Cancer

The Cytokines IL-21 and GM-CSF Have Opposing Regulatory Roles in the Apoptosis of Conventional Dendritic Cells

(2013) Chi-Keung Wan et al.   IMMUNITY

The Early Activation Marker CD69 Regulates the Expression of Chemokines and CD4 T Cell Accumulation in Intestine

(2013) Katarina Radulovic et al.   PLoS One

IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis

(2012) K. Attridge et al.   BLOOD

Interleukin-21 Receptor-Mediated Signals Control Autoreactive T Cell Infiltration in Pancreatic Islets

(2012) Tom L. Van Belle et al.   IMMUNITY

Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study

(2012) Teresa M. Petrella et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Determinants of Successful CD8 + T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice

(2011) Christopher A. Klebanoff et al.   CLINICAL CANCER RESEARCH

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy

(2010) Matthias Wölfl et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Safety and Clinical Effect of Subcutaneous Human Interleukin-21 in Patients with Metastatic Melanoma or Renal Cell Carcinoma: A Phase I Trial

(2010) H. Schmidt et al.   CLINICAL CANCER RESEARCH

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial

(2009) I. D. Davis et al.   CLINICAL CANCER RESEARCH

T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity

(2009) Natalia Martin-Orozco et al.   IMMUNITY

Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma

(2008) John A. Thompson et al.   JOURNAL OF CLINICAL ONCOLOGY

Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity

(2007) Rosanne Spolski et al.   Annual Review of Immunology